



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ :

A61K 37/54, C12N 9/36

A1

(11) International Publication Number:

WO 94/01127

(43) International Publication Date:

20 January 1994 (20.01.94)

(21) International Application Number: PCT/EP93/01841

(22) International Filing Date: 13 July 1993 (13.07.93)

(30) Priority data:

P-295273

13 July 1992 (13.07.92)

PL

(71) Applicants (for all designated States except US): NIKA HEALTH PRODUCTS LIMITED [LI/LI]; Stästle 36, FL-9490 Vaduz (LI). ROSENICH, Paul [AT/LI]; Meierhofstrasse 94, FL-9495 Triesen (LI).

(72) Inventor: and

(75) Inventor/Applicant (for US only): KICZKA, Witold [PL/US]; 8 Lawrenceville Road, Princeton, NJ 08540 (US).

(74) Agent: PATENTBÜRO DR. BUECHEL; Letzanaweg 25, FL-9495 Triesen (LI).

(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

= EP 93915903.4.

(54) Title: LYSOZYME DIMER AND COMPOSITIONS CONTAINING THE SAME

(57) Abstract

The invention relates to new uses of the dimerised form of lysozyme for the manufacture of a medicament for inhibiting biosynthesis of Tumor Necrosis Factor in animals and humans. The lysozyme dimer is in particular useful for the treatment and prophylaxis of diseases associated with excessively high levels of Tumor Necrosis Factor. The invention further relates to pharmaceutical formulations of the medicament according to the invention, namely injections comprising the dimerised form of lysozyme in amounts of 0.01-10 mg/ml, of an apyrogenic sterile composition comprising at least one physiologically acceptable solvent and at least one pharmaceutically approved preservative, as well as to tampons and antiseptic dressings impregnated with, and ointments or gels comprising an effective dose of the dimerised form of lysozyme for the prevention and/or treatment of sepsis and septic shock, especially of infected wounds.

This Sheet Has Been Replaced



THIS SHEET HAS BEEN
REPLACED